|
| For news sources visit the bottom of the post. |
Recently Pfizer's insistency on its indemnity against lawsuits in case of
adverse effects linked to its jab has become a major hurdle for its
COVID-19 vaccine obtaining approval in
India. The discussions are essentially stalled over the
indemnity issue. People told Economic Times.
Pfizer has signed an indemnity clause with many other countries that are using its vaccine, absolving the
company from paying any legal cost in case of an adverse event.
On Monday, Pfizer's CEO
Albert Bourla said that the company was
in discussion with the Indian government seeking an "expedited approval pathway" for its CORONAVIRUS vaccine while announcing the US drugmaker's donation of
medicines worth more than $70 million (Rs.517 crore) to the
country.
As said by Government officials, Unlike many other countries, India doesn't
offer any protection against adverse effects such as serious illness or death
caused by the vaccine.
"This cannot be given to one company. If it is given to Pfizer then the
domestic companies will ask for the same too," one of the officials
said.
The Indian government, while granting emergency licences to
Serum Institute of India's Covishield and
Bharat Biotech's Covaxin, did not accept their demand for
Indemnity against such adverse effects.
Sources : The Economic Times
Thanks,
TEAM TTIN.
Comments
Post a Comment